



ANTIOXIDANT – MEDIATED GLUTATHIONE LEVELS OF GLUCOSE – 6 – PHOSPHATE DEHYDROGENASE – DEFICIENT ERYTHROCYTES UNDER DRUG-INDUCED OXIDATIVE STRESS.

¹Aloh, G. S, ^{2*}Obeagu, Emmanuel Ifeanyi, ³Okoroiwu, I.L., ¹Odo, Christian Emeka,
²Odo Matthew Chibunna, ⁴Kanu,S.N, ⁵Elemchukwu, Q., ⁵Okpara,K.E.,
⁶Ugwu, Getrude Uzoma,

¹Department of Biochemistry, Michael Okpara University of Agriculture, Umudike, Abia
State, Nigeria.

²Diagnostic Laboratory Unit, University Health Services, Michael Okpara University of
Agriculture, Umudike, Abia State, Nigeria.

³Department of Medical laboratory Science, Imo State University, Owerri, Nigeria.

⁴Abia State University Teaching Hospital, Aba, Abia State, Nigeria.

⁵Rivers State College of Health Technology, Port Harcourt.

Article Received on 21/12/2014

Article Revised on 16/01/2015

Article Accepted on 09/02/2015

***Correspondence for**

Author

Obeagu, E.I.

Diagnostic Laboratory
Unit, University Health
Services, Michael Okpara
University of Agriculture,
Umudike, Abia State,
Nigeria. +2348037369912

emmanulobeagu@yahoo.com
obeagu.emmanuel@mouau.edu.ng

ABSTRACT

The effects of two antioxidants, ascorbic acid and α -tocopherol, on the glutathione (GSH) levels of glucose – 6 – phosphate dehydrogenase (G6PD) – deficient erythrocytes were studied before inducing oxidative stress with acetylphenylhydrazine (APHZ), and after inducing the stress, followed separately with ascorbic acid and α – tocopherol treatments. Before APHZ treatment, the mean GSH levels in the control and G6PD – deficient erythrocytes were 38.82 ± 1.48 mg/100ml and 36.00 ± 2.44 mg/100ml respectively. Their respective mean post – APHZ levels were 37.00 ± 2.35 mg/100ml and

17.00 ± 0.01 mg/100ml. Post – APHZ + ascorbic acid, the control's mean GSH level was 37.75 ± 2.50 mg/100ml and the mean level in the G6PD – deficient cells was 27.00 ± 3.44 mg/100ml, while their respective post – APHZ + α – tocopherol levels were 38.76 ± 2.00 mg/100ml (control) and 33.00 ± 1.93 mg/100ml (G6PD – deficient red cells). The results of this study indicate that the initial effect of an oxidant drug on erythrocytes is to lower their GSH levels. This effect was found to be more severe in G6PD – deficient red cells than in the

non – deficient ones. Ascorbic acid and α - tocopherol could ameliorate the effect of this oxidant stressor, and possibly others, but the latter was more effective. Its fat – solubility is suspected to be responsible for this enhanced efficacy.

KEYWORDS: Antioxidants; Glucose -6 -phosphate dehydrogenase; oxidative stress; ascorbic acid; α – tocopherol.

INTRODUCTION

The severe and fatal haemolytic anaemia that attended the introduction of primaquine in the 1920s to cure resistant or relapsing forms of *Plasmodium vivax* and *P. falciparum* brought this drug to a notorious clinical notice . A study in 1953 revealed the cause of this anaemia to be an X – linked lesion of the erythrocyte due to a deficiency or low activity of glucose – 6 – phosphate dehydrogenase (G6PD)^[2]. This lesion, also called *primaquine sensitivity*, is now a generic reference to primaquine and many other forms of drug – induced haemolytic anaemia since it is inducible with over 100 known oxidant drugs in susceptible individuals^[3]. The low activity of G6PD in susceptible erythrocytes is due to the accelerated breakdown of the mutant enzyme protein leading to a defective pentose phosphate pathway and low levels of NADPH in such red cells ^[4].Consequently , oxidized erythrocyte glutathione (GSSG) cannot be effectively reduced to the erythro-protective thiol (GSH), thereby exposing the red cells to assault by free radicals and other oxidant species ^[5].

The primary line of defence against free radicals is a battery of enzymes: glutathione peroxidase (GPx), superoxide peroxidase (SOD) and catalase ^[6], while the secondary defence is provided by antioxidants, including vitamins A,C and E, as well as GSH, etc,^[7] The oxidative stress caused by an imbalance between the rates of production and removal of free radicals has been implicated in the pathogenesis and progression of many diseases and metabolic derangements^[8].

In this study, the effects of two antioxidants, ascorbic acid and *alpha* – tocopherol, on the glutathione levels of G6PD – deficient erythrocytes in which oxidative stress was induced with 5mg of acetylphenylhydrazine (APHZ) per ml of whole blood are reported.

MATERIALS AND METHODS

Volunteers and Blood Samples:- With the consents of the volunteers, the method of Beutler & Mitchell ^[9] was used to select 60 individuals for the study. They were 30 G6PD –

deficient individuals and 30 G6PD – non-deficient ones who served as the control. About 5ml of venous blood was collected from each volunteer and transferred into a venoject tube containing Na- citrate, an anticoagulant.

Chemicals: All the chemicals used for this study were of analytical grades and products of reputable companies.

GSH Assay ^[10]: One ml of whole venous blood was drawn into 1ml of acid – citrate – D- glucose (ACD) solution made up of 16.0g of sodium citrate, 4.8g of citric acid, and 29.5g of glucose in one litre of distilled water. 5mg of acetylphenylhydrazine (APHZ) per ml of blood was added to induce oxidative stress , mixed, shaken to ensure thorough oxygenation, and incubated for 2hours at 37⁰C in a water-bath. To test the effect of ascorbic acid on both APHZ – induced oxidative stress and the GSH levels of the erythrocytes, 0.08mg of ascorbic acid per ml of blood was added to the reaction mixture after the addition of APHZ, and incubated for 2 hours. For the effect of α – tocopherol, 0.1mg of vitamin E per ml of blood was added at that point to a separate, similarly - treated reaction mixture, and also incubated for 2 hours. After the incubation, 2ml of distilled water was added. Five minutes later, 5ml of 3% glacial metaphosphoric acid was added with agitation, followed with 3g of NaCl. The reaction mixture was shaken, filtered , and 2ml of the filtrate added to 6ml of saturated NaCl solution in a 25-ml cuvette at a temperature of 20 – 25⁰C. One ml of 2% sodium nitroprusside and 1ml of 0.67M NaCN – 5M NaCO₃ (1:1,v/v) solution were added to develop colour. A spectrophotometer reading was made at 525nm *within one minute*.

Table 1: GSH levels in erythrocytes before and after APHZ and antioxidant treatments.

Red Cell Type	Pre – APHZ (mg/100 ml)	Post – APHZ (mg/ 100ml)	Post – APHZ + Ascorb acid (mg/ 100ml)	Post – APHZ + α – Tocopherol (mg/ 100ml)
Control	39.82 \pm 1.48	37.00 \pm 2.35	37.75 \pm 2.50	38.76 \pm 2.00
G6PD Deficient	36.00 \pm 2.44	17.00 \pm 0.01	27.00 \pm 3.44	33.00 \pm 1.93

DISCUSSION

Prior to the induction of oxidative stress with APHZ in the red cells studied, G6PD – deficient erythrocytes had a lower mean GSH level than the control (Table 1). This was suggestive of a subsisting oxidant challenge, even in the absence of an exogenous oxidative stress.

Although the control red cells should have optimal G6PD activity to generate NADPH to reduce GSSG to the erythro – protective GSH, there was a significant fall ($p < 0.05$) in the mean GSH level of these cells upon exposure to APHZ. However, when the APHZ – treated red cells were exposed to ascorbic acid, an antioxidant, there was a significant elevation ($p < 0.05$) of the mean GSH level of the erythrocytes. Exposure of the APHZ – treated cells to α – tocopherol also caused a significant ($p < 0.05$) elevation of their mean GSH level, such that the difference between their mean pre – and post – APHZ treatment levels became insignificant ($p > 0.05$). It is inferable from the above changes that, the initial effect of an oxidant drug (e.g. , APHZ) on erythrocytes is to lower their GSH levels. Since red cell GSH is maintained in the reduced state by the NADPH generated in the G6PD – catalyzed reaction in the pentose phosphate pathway, it is also reasonable to infer that the initial effect of an oxidant drug is to lower the activity of this enzyme, so that less NADPH is available to reduce GSSG to GSH. This must have accounted, at least in part, for the reduced mean level of this intracellular thiol (GSH) when the cells were exposed to APHZ *ab initio*.

Alternatively, the lowering of GSH level could have occurred through the activation of γ – glutamyltranspeptidase, an enzyme located on the external surfaces of red cells, and known to initiate the degradation of GSH *in vivo* ^[11]. Irrespective of the mechanism of down – regulating the red cell GSH levels upon exposure to oxidant drugs, it was observed that the two antioxidants, ascorbic acid and α – tocopherol, mediated their up-regulation although to varying extents. The effect of ascorbic acid, although significant ($p < 0.05$), was less profound than that of α – tocopherol. It is probable that the latter's fat-solubility enabled it to so - penetrate the erythrocyte membrane lipids and scavenge the offending redox species that, the mean GSH level of the control red cells was elevated close to their pre – APHZ treatment level.

The treatment of the G6PD – deficient red cells with APHZ caused a significant fall ($p < 0.05$) in their mean GSH level. As speculated for the “G6PD –normal” cells, the activity of G6PD needed to generate NADPH to reduce GSSG to GSH was lowered by APHZ. Similarly, APHZ could also have activated γ - glutamyltranspeptidase that initiates the degradation of G6PD enzyme protein (Goldberg & Rock, 1992). Both ascorbic acid and α – tocopherol elevated the mean GSH levels of the erythrocytes but that of G6PD – deficient ones still remained significantly lower ($p < 0.05$) than the pre – APHZ level. It is most likely that

overwhelming levels of redox species were generated and sustained when the red cells were treated with APHZ.

In conclusion, the effect of the oxidant drug (APHZ) was found to be more severe in G6PD – deficient erythrocytes than in the non – deficient ones. Irrespective of red cell type however, this study revealed that the initial effect of the oxidant drug (and possibly others) is to lower the activity of G6PD probably by accelerating the γ – glutamyltranspeptidase - mediated degradation of its enzyme protein. Furthermore, ascorbic acid and α – tocopherol ameliorated the effect of the oxidant but the latter was more effective, probably because it is fat – soluble. By implication, the co – administration of ascorbic acid or α – tocopherol with oxidant drugs, especially oxidant anti-malarial drugs, such as 4 – and 8 – aminoquinolines, to which G6PD – deficient individuals react adversely, will stabilize or restore erythrocyte GSH levels.

REFERENCES

1. Bhatia, S. C., Seraph, Y. S., Ravenker, S. N., Doshi, K.I., Barucha, E. D., Desai, N. K., Vaidya, A. B., Subrahmanyam, D., Gupta, K. C. & Satoskar, R. S. Pharmacokinetics of Primaquine in Patients with *P. vivax* malaria. *European Journal of Clinical Pharmacology*, 1986; 31: 205 – 210.
2. Price, A. H. & Fletcher, K. A. The metabolism and toxicity of primaquine. *Progress in Clinical Biology Research*, 1986; 214: 261 – 278.
3. Bowman, Z. S., Morrow, J.D., Jollow, D. J. & McMillan, D. C. Primaquine – induced anemia: role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5 – hydroxyprimaquine. *Journal of Pharmacology and Experimental Therapeutics*, 2005; 314(2): 838 – 845.
4. Goldberg, A. L. & Rock, K. L. Proteolysis, Proteosomes and Antigen Presentation. *Nature*, 1992; 357: 375 – 379.
5. Mehta, A., Mason, P. J. & Vulliamy, T. J. Glucose - 6 – phosphate dehydrogenase deficiency. *Practical Research in Clinical Hematology*, 2000; 13: 21 – 28.
6. Dhalla, N. S., Emoselhi, A. B., Hata, T. & Makino, N. Status of myocardial antioxidants in ischemia – reperfusion injury. *Cardiovascular Research*, 2000; 13: 21–28.
7. Uday, B., Dipak, D. & Benerjee, R. K. Reactive oxygen species : Oxidative damage and pathogenesis (A Review). *Current Science*, 1999; 77: 658 – 663.

8. Bilgin – Karabulut, A., Ademoglu, E., Aydin., I., Erer, M.& Gukkосу, C. Protective effects of vitamins A and E pre-treatment in reperfusion injury. *Journal of Reconstructive and Microsurgery*, 2001; 17: 425 – 429.
9. Beutler, E. & Mitchel, M. Special modifications of the fluorescent screening method for glucose – 6 - phosphate dehydrogenase deficiency. *Blood*, 1968; 32: 816 – 818.
10. Beutler, E. A series of new screening procedures for pyruvate kinase, glucose – 6 – phosphate, and glutathione. *Blood*, 1966; 28: 553–562.
11. Voet, D. & Voet, J. G. *Biochemistry*. Second Edition. New York: John Wiley & Sons, 1995; pp.595 – 780.